Detalles de la búsqueda
1.
Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet
; 403(10423): 249-260, 2024 Jan 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-38048786
2.
Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes.
Blood
; 141(17): 2047-2061, 2023 04 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-36724453
3.
Germline assessment for alloHSCT candidates over 50 years: A 'Fast-Track' screening in myeloid neoplasms.
Br J Haematol
; 2024 Apr 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-38639421
4.
Validation of the Artificial Intelligence Prognostic Scoring System for Myelodysplastic Syndromes in chronic myelomonocytic leukaemia: A novel approach for improved risk stratification.
Br J Haematol
; 204(4): 1529-1535, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38411250
5.
Guiding the global evolution of cytogenetic testing for hematologic malignancies.
Blood
; 139(15): 2273-2284, 2022 04 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-35167654
6.
Treatment of post-allogeneic hematopoietic stem cell transplant cytopenias with sequential doses of multipotent mesenchymal stromal/stem cells.
Cytotherapy
; 2024 Apr 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-38727653
7.
Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes.
N Engl J Med
; 382(2): 140-151, 2020 01 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-31914241
8.
Improved benefit of continuing luspatercept therapy: sub-analysis of patients with lower-risk MDS in the MEDALIST study.
Ann Hematol
; 102(2): 311-321, 2023 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-36635381
9.
Predictors of cardiovascular events and all-cause of death in patients with transfusion-dependent myelodysplastic syndrome.
Br J Haematol
; 195(4): 536-541, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34180544
10.
Myelodysplastic syndromes with 20q deletion: incidence, prognostic value and impact on response to azacitidine of ASXL1 chromosomal deletion and genetic mutations.
Br J Haematol
; 194(4): 708-717, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-34296432
11.
Co-occurrence of cohesin complex and Ras signaling mutations during progression from myelodysplastic syndromes to secondary acute myeloid leukemia.
Haematologica
; 106(8): 2215-2223, 2021 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32675227
12.
Genome-wide transcriptomics leads to the identification of deregulated genes after deferasirox therapy in low-risk MDS patients.
Pharmacogenomics J
; 20(5): 664-671, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32015457
13.
The Incorporation of Extracellular Vesicles from Mesenchymal Stromal Cells Into CD34+ Cells Increases Their Clonogenic Capacity and Bone Marrow Lodging Ability.
Stem Cells
; 37(10): 1357-1368, 2019 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31184411
14.
Deferasirox reduces oxidative DNA damage in bone marrow cells from myelodysplastic patients and improves their differentiation capacity.
Br J Haematol
; 187(1): 93-104, 2019 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31172513
15.
Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial.
Blood
; 139(4): 624-629, 2022 01 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-34758066
16.
Chronic graft-versus-host disease could ameliorate the impact of adverse somatic mutations in patients with myelodysplastic syndromes and hematopoietic stem cell transplantation.
Ann Hematol
; 98(9): 2151-2162, 2019 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-31312927
17.
Mesenchymal Stromal Cell Irradiation Interferes with the Adipogenic/Osteogenic Differentiation Balance and Improves Their Hematopoietic-Supporting Ability.
Biol Blood Marrow Transplant
; 24(3): 443-451, 2018 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-29155314
18.
Transcriptomic rationale for synthetic lethality-targeting ERCC1 and CDKN1A in chronic myelomonocytic leukaemia.
Br J Haematol
; 182(3): 373-383, 2018 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-29797327
19.
Azacitidine improves outcome in higher-risk MDS patients with chromosome 7 abnormalities: a retrospective comparison of GESMD and GFM registries.
Br J Haematol
; 181(3): 350-359, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29611196
20.
Enumerating bone marrow blasts from nonerythroid cellularity improves outcome prediction in myelodysplastic syndromes and permits a better definition of the intermediate risk category of the Revised International Prognostic Scoring System (IPSS-R).
Am J Hematol
; 92(7): 614-621, 2017 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-28370234